Japan’s KM Biologics enters into technology collaboration with Serum Institute of India
May 3, 2026 | Sunday | News
For the establishment of a stable supply for Japanese encephalitis vaccines in India
image credit- freepik
Japan-based Meiji Seika Pharma Co. has announced that KM Biologics Co., a group company of Meiji Seika Pharma, has entered into a technology collaboration with Serum Institute of India Private Limited (SII), a Cyrus Poonawalla group company and the world’s largest vaccine manufacturer, for the development and manufacturing of a Japanese encephalitis vaccine, and has achieved the first milestone under this collaboration.
This collaboration has been carried out based on a technology transfer agreement between KM Biologics and SII for the development and manufacturing of a Japanese encephalitis vaccine.
With the achievement of this milestone, SII will initiate development activities in India for the Japanese encephalitis vaccine currently manufactured and marketed by KM Biologics. Going forward, the two companies will work closely together to advance development and to establish manufacturing and supply by SII.
Japanese encephalitis remains a significant public health challenge, particularly in Asia, and continues to be a major infectious disease concern. In India, there is a strong demand for a stable and large-scale supply of vaccines under the national immunization program.
Leveraging the expertise in vaccine research, development, manufacturing, and quality control that they have cultivated over the years, Meiji Seika Pharma and KM Biologics have positioned contributing to global infectious disease control as a key mission.
Through collaboration with SII, which possesses one of the world’s largest vaccine manufacturing capacities, the establishment of a stable supply for Japanese encephalitis vaccines in India and contributions to public health are expected.
Meiji Seika Pharma is advancing its business expansion primarily in regions across the Global South. This collaboration with SII will serve as an important foundation for future business development, and by maximising its strong sales channels, particularly in Asia, the company will continue to contribute to the improvement of global public health.